Table 1.
Baseline clinical characteristics.
| Clinical characteristics | Retrospective (n = 32) |
Prospective (n = 29) |
Overall (n = 61) |
P |
|---|---|---|---|---|
| Age (years) | 63.5 ± 4.5 | 55 ± 5.7 | 55 ± 3.72 | 0.0409 |
| Male, n (%) | 31 (96.9) | 23 (79.4) | 54 (88.5) | 0.031 |
| Family history of SCD, n (%) | 1 (3.57) | 8 (40.0) | 9 (15.8) | 0.009 |
| Hypertension, n (%) | 13 (40.6) | 15 (51.7) | 28 (45.9) | 0.385 |
| Dyslipedemia, n (%) | 9 (28.1) | 13 (44.8) | 22 (36.1) | 0.174 |
| Diabetes, n (%) | 7 (21.9) | 3 (10.3) | 10 (16.4) | 0.224 |
| Smoking habit, n (%) | 12 (37.5) | 13 (44.8) | 22 (36.1) | 0.561 |
| Atrial fibrillation, n (%) | 5 (15.6) | 6 (20.7) | 11 (18) | 0.849 |
| Heart failure, n (%) | 10 (31.3) | 6 (20.7) | 12 (26.2) | 0.234 |
| Previous myocardial infarction, n (%) | 6 (18.8) | 8 (27.6) | 14 (22.9) | 0.654 |
| Previous revascularization, n (%) | 4 (12.5) | 4 (13.8) | 6 (13.1) | 0.402 |
| Previous stroke, n (%) | 1 (3.1) | 1 (3.4) | 2 (3.3) | 0.943 |
| Chronic renal failure, n (%) | 2 (6.3) | 0 (0) | 2 (3.3) | 0.271 |
| DCM, n (%) | 2 (6.3) | 0 (0) | 2 (3.3) | 0.17 |
| COPD, n (%) | 3 (9.4) | 5 (17.2) | 8 (13.1) | 0.363 |
| HCM, n (%) | 0 (0) | 3 (10.3) | 3 (4.9) | 0.101 |
| Severe valvulopathy, n (%) | 2 (6.3) | 1 (3.4) | 3 (4.9) | 0.613 |
| Preexcitation, n (%) | 0 (0) | 1 (3.4) | 1 (1.6) | 0.289 |
| Time to ALS, (min) | 8 ± 2.4 | 8 ± 2.0 | 8 ± 1.5 | 0.887 |
| Time performing ALS, (min) | 15 ± 5.9 | 10 ± 5.3 | 15 ± 3.9 | 0.282 |
| Number of shocks delivered before ROSC | 3.5 ± 1.6 | 3 ± 0.87 | 3 ± 0.9 | 0.185 |
| Background treatment | ||||
| Aspirin, n (%) | 4 (12.5) | 5 (17.2) | 9 (14.7) | 0.602 |
| Thienopyridines, n (%) | 1 (3.1) | 0 (0) | 1 (1.6) | 0.524 |
| Betablockers, n (%) | 7 (21.9) | 9 (31) | 16 (26.2) | 0.416 |
| Amiodarone, n (%) | 2 (6.3) | 0 (0) | 2 (3.3) | 0.271 |
| ACE inhibitors, n (%) | 6 (18.8) | 7 (24.1) | 13 (21.3) | 0.557 |
| ARBs, n (%) | 1 (3.1) | 3 (10.3) | 4 (6.6) | 0.239 |
| Statins, n (%) | 8 (25) | 10 (34.5) | 18 (29.5) | 0.417 |
| Calcium antagonists, n (%) | 1 (3.1) | 2 (6.9) | 3 (4.9) | 0.496 |
| Diuretics, n (%) | 8 (25) | 6 (20.7) | 14 (22.9) | 0.689 |
| Aldosterone inhibitors, n (%) | 1 (3.1) | 2 (6.9) | 3 (4.9) | 0.476 |
| Anticoagulants, n (%) | 5 (15.6) | 6 (20.7) | 12 (19.7) | 0.849 |
ROSC: return of spontaneous circulation. DCM: dilated cardiomyopathy. COPD: chronic obstructive pulmonary disease. HCM: hypertrophic cardiomyopathy. ALS: advanced life support. ACE: angiotensin-converting enzyme. ARBs: Angiotensin II receptor blockers.